Abstract
Inflammation contributes to development and progression in a variety of cancers, including cervical cancer. We developed a novel cervical cancer systemic inflammation score (CCSIS) based on the preoperative platelet-to-lymphocyte ratio (PLR) and serum albumin levels. A retrospective analysis of clinical data from 795 patients with operable cervical cancer was then conducted to investigate the prognostic value of CCSIS and its association with the patients' clinicopathological features, overall survival (OS), and disease-free survival (DFS). CCSIS was predictive of OS and DFS. High CCSIS was correlated with more advanced FIGO stages, poor tumor differentiation, and the presence of PLN and LVSI. Both albumin levels and the PLR were independent prognostic indicators for operable cervical cancer. The use of the CCSIS could improve risk stratification and traditional clinicopathological analysis in cervical cancer.
Highlights
Emerging evidence suggests that inflammation plays a key role in the initiation and progression of various cancers, including cervical cancer
The clinicopathological characteristics and prognoses of 795 cervical cancer patients were investigated in this retrospective study
Univariate Cox proportional hazard analysis revealed that platelet to lymphocyte ratio (PLR), serum albumin, FIGO stage, tumor differentiation, pelvic lymph node metastasis (PLN), and lymph node invasion (LVSI), but not neutrophil to lymphocyte ratio (NLR), were associated with overall survival (OS) and disease-free survival (DFS)
Summary
Emerging evidence suggests that inflammation plays a key role in the initiation and progression of various cancers, including cervical cancer. Inflammation-based prognostic indicators, such as the modified Glasgow Prognostic Score (mGPS) [3, 4], platelet to lymphocyte ratio (PLR) [5, 6], neutrophil to lymphocyte ratio (NLR) [5,6,7], albumin, and C-reactive protein (CRP) [8, 9] are prognostic factors for cervical cancer as well as other cancers. These cost-effective biomarkers are used routinely in clinical settings and could be used to provide information regarding patient outcomes. To the best of our knowledge, integration of individual biomarkers to enhance the outcome prediction for cervical cancer has not yet been studied
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
